NewsRoom Articles - Page 132 of 214

MondayNov 29, 2021 9:30 am

AI Solutions May Make Screening for Breast Cancer More Affordable, Accessible

Research has found that breast cancer is the most commonly diagnosed cancer in women in India. This type of cancer also takes second place among the most common cancer types around the globe, with figures showing that of the more than 680,000 women who succumb to this fatal cancer annually, some 90,000 are in India. Researchers believe that one of the primary reasons behind the high rate of mortality in India is that symptoms in most patients present during the advanced stages of the ailment. Efforts to increase breast cancer awareness and population-scale screening with methods for early detection could…

MondayNov 29, 2021 9:30 am

RYAH Group Inc. (CSE: RYAH) Releases Overview of UK Cannabis Market

Market analysts place high hopes on the potential of the United Kingdom market Growing demand from patients and patient families brought the country’s medical cannabis program to a tipping point RYAH is committed to providing valuable insight and transforming patient care through big data and artificial intelligence After three years of medical cannabis being legal in the United Kingdom, the country has a total of only three patients with a prescription in the entire public system, noted a recent blog from RYAH Group (CSE: RYAH). The article noted that many more patients receive cannabis-derived medications, including flower and cannabis oil,…

MondayNov 29, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays

People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivity Tryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high unmet needs The company has submitted several IND applications for Phase 2a studies evaluating TRP-8802’s effectiveness in patients with chronic pain and select eating disorders There is no denying that food is a…

MondayNov 29, 2021 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs

InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders Preclinical data of INM-088, the company’s…

WednesdayNov 24, 2021 9:30 am

Study Investigates Influence of Ethnicity on Surviving Brain Tumors

New research has found that white British individuals who have been diagnosed with a malignant brain tumor have a higher risk of mortality than those from other ethnicities. The research’s findings were presented at the NCRI Festival. The study assessed the influence of an individual’s ethnicity on their rate of survival of a brain tumor. The researchers found that individuals who are classified under other ethnic groups had 30% lower chances of mortality in one year after being diagnosed with a malignant brain tumor. For the study, Hiba Wanis, a research assistant at King’s College London’s Centre for Cancer, Society…

TuesdayNov 23, 2021 9:30 am

Data Analytics Finds Disparities in Pregnancy Outcomes

Data analytics shows that ethnic and racial minority patients with systemic lupus erythematosus are disproportionately affected when it comes to pregnancy outcomes, despite the improvements seen over the last couple of years. In a press release, Bella Mehta, a rheumatologist at Hospital for Special Surgery and the lead author of a recent study, stated that these improvements were more apparent in some groups in comparison to others, explaining that Hispanics and African Americans still had poor pregnancy outcomes. Mehta noted that more research was needed to determine where resources were required to improve care and access for these patients. For…

MondayNov 22, 2021 9:30 am

Researchers Identify Molecular Mechanism Controlling the Development of Chronic Pain

Chronic pain is a huge problem that affects more than 1.5 billion individuals across the globe. It is defined as persistent pain that lasts anywhere between a couple of weeks to years. This pain usually evolves from acute pain that is caused by tissue damage owing to an injury or surgery. Researchers consider nerve damage to be a crucial factor in the transition to chronic pain. However, the events underlying the emergence of chronic pain hadn’t previously been discovered — until now. New research from the University of California, Irvine has found the molecular mechanisms that control the transition from…

MondayNov 22, 2021 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland

Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in Miami He shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experience Dr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for smoking cessation, set to commence in early 2022, building on the success of this recent study Mydecine is also set to support Dr. Johnson’s concurrent NIDA grant-funded study through the provision of MYCO-001 for research Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), back in September…

MondayNov 22, 2021 8:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment

Pharmaceutical company Tryp Therapeutics is investigating the potential of synthetic psychedelic drug candidates to treat unmet medical needs The company is evaluating two drug products labeled TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome and select eating disorders The company has filed its first two INDs with the FDA for planned Ph 2a clinical trials relating to fibromyalgia and eating disorder treatments In the wake of changes recommended by the FDA to the eating disorders trial, Tryp is in the process of updating its protocols and patient consent form to meet the FDA’s expectations Tryp…

FridayNov 19, 2021 9:30 am

Large Trial Finds Psilocybin Efficacious Against Depression

Compass Pathways recently released results from a phase 2b trial, which was focused on evaluating the effectiveness of psilocybin as a treatment for depression. The results, which were announced earlier last week, show that the psychedelic substance was highly effective as a treatment for treatment-resistant depression. For their study, the researchers recruited more than 200 sites in different locations in North America and Europe. This study was the largest double-blind randomized controlled trial on psilocybin, which is an active compound found in hallucinogenic mushrooms. The company stated that it observed a significant reduction in symptoms of depression in patients who…